Literature DB >> 22873215

Non-coding RNAs as therapeutic targets in hepatocellular cancer.

Chiara Braconi1, Tushar Patel.   

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy that affects a large number of patients worldwide, with an increasing incidence in the United States and Europe. The therapies that are currently available for patients with inoperable HCC have limited benefits. Although molecular targeted therapies against selected cell signaling pathways have shown some promising results, their impact has been minimal. There is a need to identify and explore other targets for the development of novel therapeutics. Several non-protein coding RNAs (ncRNA) have recently been implicated in hepatocarcinogenesis and tumor progression. These ncRNA genes represent promising targets for cancer. However, therapeutic targeting of ncRNA genes has not been employed for HCC. The use of antisense oligonucleotides and viral vector delivery approaches have been shown to be feasible approaches to modulate ncRNA expression. HCC is an optimal cancer to evaluate novel RNA based therapeutic approaches because of the potential of effective delivery and uptake of therapeutic agents to the liver. In this review, we discuss selected ncRNA that could function as potential targets in HCC treatment and outline approaches to target ncRNA expression. Future challenges include the need to achieve site-specific targeting with acceptable safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22873215      PMCID: PMC3916140     

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  54 in total

1.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Authors:  Andrea Annoni; Brian D Brown; Alessio Cantore; Lucia Sergi Sergi; Luigi Naldini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

2.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

3.  Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis.

Authors:  Chun-Ming Wong; Carmen Chak-Lui Wong; Joyce Man-Fong Lee; Dorothy Ngo-Yin Fan; Sandy Leung-Kuen Au; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2012-05       Impact factor: 17.425

4.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

Authors:  James Heyes; Lorne Palmer; Kaz Bremner; Ian MacLachlan
Journal:  J Control Release       Date:  2005-10-03       Impact factor: 9.776

5.  MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2).

Authors:  Seonhoe Kim; Ui Jin Lee; Mi Na Kim; Eun-Ju Lee; Ji Young Kim; Mi Young Lee; Sorim Choung; Young Joo Kim; Young-Chul Choi
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

6.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

7.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

8.  Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.

Authors:  Kazutaka Nishina; Toshinori Unno; Yoshitaka Uno; Takayuki Kubodera; Tadashi Kanouchi; Hidehiro Mizusawa; Takanori Yokota
Journal:  Mol Ther       Date:  2008-02-12       Impact factor: 11.454

9.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

View more
  18 in total

Review 1.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

2.  Therapeutic actions of melatonin on gastrointestinal cancer development and progression.

Authors:  Rachael Glenister; Kelly McDaniel; Heather Francis; Julie Venter; Kendal Jensen; Giuseppina Dusio; Eugenio Gaudio; Shannon Glaser; Fanyin Meng; Gianfranco Alpini
Journal:  Transl Gastrointest Cancer       Date:  2013-01-01

3.  MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma.

Authors:  Hui Liu; Wenzheng Li; Changyong Chen; Yigang Pei; Xueying Long
Journal:  Tumour Biol       Date:  2015-03-25

Review 4.  Long noncoding RNA in liver diseases.

Authors:  Kenji Takahashi; Irene Yan; Hiroaki Haga; Tushar Patel
Journal:  Hepatology       Date:  2014-06-20       Impact factor: 17.425

5.  Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells.

Authors:  Hui-Chao Zhou; Jian-Hong Fang; Xu Luo; Lei Zhang; Jine Yang; Chong Zhang; Shi-Mei Zhuang
Journal:  Oncotarget       Date:  2014-12-15

Review 6.  Non-Coding RNAs in Primary Liver Cancer.

Authors:  Michele Ghidini; Chiara Braconi
Journal:  Front Med (Lausanne)       Date:  2015-06-04

7.  MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN.

Authors:  Jianxin Jiang; Yi Zhang; Chao Yu; Zhipeng Li; Yaozheng Pan; Chengyi Sun
Journal:  Cancer Cell Int       Date:  2014-09-20       Impact factor: 5.722

8.  MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer.

Authors:  Lionel Lim; Asha Balakrishnan; Noelle Huskey; Kirk D Jones; Mona Jodari; Raymond Ng; Guisheng Song; Jesse Riordan; Brittany Anderton; Siu-Tim Cheung; Holger Willenbring; Adam Dupuy; Xin Chen; David Brown; Aaron N Chang; Andrei Goga
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

9.  Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.

Authors:  Kenji Takahashi; Irene K Yan; Takayuki Kogure; Hiroaki Haga; Tushar Patel
Journal:  FEBS Open Bio       Date:  2014-05-09       Impact factor: 2.693

Review 10.  Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer.

Authors:  Swathi Mohankumar; Tushar Patel
Journal:  Brief Funct Genomics       Date:  2015-12-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.